IL319478A - Anti-ccr8 antibodies - Google Patents

Anti-ccr8 antibodies

Info

Publication number
IL319478A
IL319478A IL319478A IL31947825A IL319478A IL 319478 A IL319478 A IL 319478A IL 319478 A IL319478 A IL 319478A IL 31947825 A IL31947825 A IL 31947825A IL 319478 A IL319478 A IL 319478A
Authority
IL
Israel
Prior art keywords
ccr8
antibody
antibodies
seq
cells
Prior art date
Application number
IL319478A
Other languages
English (en)
Hebrew (he)
Inventor
Andrew J Mccluskey
Paustian Amanda M Schmidt
Jane Seagal
Julie L Wilsbacher
Original Assignee
Abbvie Inc
Andrew J Mccluskey
Paustian Amanda M Schmidt
Jane Seagal
Julie L Wilsbacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc, Andrew J Mccluskey, Paustian Amanda M Schmidt, Jane Seagal, Julie L Wilsbacher filed Critical Abbvie Inc
Publication of IL319478A publication Critical patent/IL319478A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/40Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41Glycosylation, sialylation, or fucosylation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL319478A 2021-07-27 2022-07-27 Anti-ccr8 antibodies IL319478A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163226118P 2021-07-27 2021-07-27
PCT/US2022/074214 WO2023010054A1 (en) 2021-07-27 2022-07-27 Anti-ccr8 antibodies

Publications (1)

Publication Number Publication Date
IL319478A true IL319478A (en) 2025-05-01

Family

ID=82898810

Family Applications (2)

Application Number Title Priority Date Filing Date
IL319478A IL319478A (en) 2021-07-27 2022-07-27 Anti-ccr8 antibodies
IL307533A IL307533B2 (en) 2021-07-27 2022-07-27 Anti-ccr8 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL307533A IL307533B2 (en) 2021-07-27 2022-07-27 Anti-ccr8 antibodies

Country Status (27)

Country Link
US (1) US11639393B2 (enExample)
EP (2) EP4214240B1 (enExample)
JP (2) JP7638935B2 (enExample)
KR (2) KR20250135339A (enExample)
CN (1) CN117425677A (enExample)
AR (1) AR126578A1 (enExample)
AU (1) AU2022317803A1 (enExample)
BR (1) BR112023024837A2 (enExample)
CA (1) CA3220121A1 (enExample)
CO (1) CO2023015915A2 (enExample)
DK (1) DK4214240T3 (enExample)
ES (1) ES2995868T3 (enExample)
FI (1) FI4214240T3 (enExample)
HR (1) HRP20241561T1 (enExample)
HU (1) HUE069018T2 (enExample)
IL (2) IL319478A (enExample)
LT (1) LT4214240T (enExample)
MX (1) MX2023014154A (enExample)
PL (1) PL4214240T3 (enExample)
PT (1) PT4214240T (enExample)
RS (1) RS66234B1 (enExample)
SA (1) SA523451582B1 (enExample)
SI (1) SI4214240T1 (enExample)
SM (1) SMT202400483T1 (enExample)
TW (1) TW202321304A (enExample)
WO (1) WO2023010054A1 (enExample)
ZA (1) ZA202309516B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI832035B (zh) 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
TW202430550A (zh) 2022-10-18 2024-08-01 日商明治製菓藥業股份有限公司 T細胞性腫瘤之治療劑
TW202448461A (zh) 2023-02-06 2024-12-16 德商拜耳廠股份有限公司 Dgk(二醯基甘油激酶)抑制劑及免疫檢查點抑制劑及調節劑之組合
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025186043A1 (en) 2024-03-06 2025-09-12 Bayer Aktiengesellschaft Pharmaceutical formulation for anti-ccr8 antibodies
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US10087259B1 (en) 2014-04-28 2018-10-02 Memorial Sloan Kettering Cancer Center Depleting tumor-specific tregs
CA3023980A1 (en) 2016-05-16 2017-11-23 Checkmab S.R.L. Markers selectively deregulated in tumor-infiltrating regulatory t cells
WO2018112032A1 (en) 2016-12-13 2018-06-21 President And Fellows Of Harvard College Methods and compositions for targeting tumor-infiltrating tregs using inhibitors of ccr8 and tnfrsf8
KR102144658B1 (ko) * 2017-03-29 2020-08-14 시오노기세이야쿠가부시키가이샤 암 치료용 의약 조성물
TW202039575A (zh) 2018-12-27 2020-11-01 日商鹽野義製藥股份有限公司 新穎之抗ccr8抗體
JP7606518B2 (ja) * 2020-01-06 2024-12-25 ヴァクシネックス, インコーポレイテッド 抗ccr8抗体及びその使用
TWI832035B (zh) * 2020-02-14 2024-02-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
EP4114862A4 (en) 2020-03-05 2024-07-03 Memorial Sloan Kettering Cancer Center Anti-ccr8 agents
MX2022011701A (es) 2020-03-23 2022-10-07 Bristol Myers Squibb Co Anticuerpos anti-receptor de quimiocina 8 con motivo c-c (ccr8) para el tratamiento del cancer.
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
MX2023002511A (es) 2020-08-28 2023-04-20 Harbour Biomed Us Inc Anticuerpo anti-ccr8 y aplicacion del mismo.
CA3198456A1 (en) 2020-10-14 2022-04-21 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
MX2023004349A (es) 2020-10-16 2023-08-22 Lanova Medicines Ltd Anticuerpos monoclonales anti-ccr8 y sus usos.
CA3206124A1 (en) 2020-12-24 2022-06-30 Vib Vzw Non-blocking human ccr8 binders
EP4267617A1 (en) 2020-12-24 2023-11-01 Vib Vzw Human ccr8 binders

Also Published As

Publication number Publication date
SA523451582B1 (ar) 2025-04-26
KR20240067052A (ko) 2024-05-16
PT4214240T (pt) 2024-11-25
CN117425677A (zh) 2024-01-19
KR102860769B1 (ko) 2025-09-18
IL307533B1 (en) 2025-04-01
FI4214240T3 (fi) 2024-11-14
DK4214240T3 (da) 2024-11-18
JP2023018678A (ja) 2023-02-08
KR20250135339A (ko) 2025-09-12
MX2023014154A (es) 2024-05-14
IL307533A (en) 2023-12-01
ZA202309516B (en) 2025-03-26
PL4214240T3 (pl) 2025-01-07
LT4214240T (lt) 2024-11-25
JP2025081477A (ja) 2025-05-27
WO2023010054A1 (en) 2023-02-02
AU2022317803A1 (en) 2023-10-26
US11639393B2 (en) 2023-05-02
CO2023015915A2 (es) 2023-12-11
SMT202400483T1 (it) 2025-01-14
IL307533B2 (en) 2025-08-01
HUE069018T2 (hu) 2025-02-28
EP4214240A1 (en) 2023-07-26
EP4491635A3 (en) 2025-04-02
JP7638935B2 (ja) 2025-03-04
RS66234B1 (sr) 2024-12-31
TW202321304A (zh) 2023-06-01
EP4491635A2 (en) 2025-01-15
CA3220121A1 (en) 2023-02-02
BR112023024837A2 (pt) 2024-02-20
SI4214240T1 (sl) 2025-02-28
US20230048553A1 (en) 2023-02-16
AR126578A1 (es) 2023-10-25
HRP20241561T1 (hr) 2025-02-14
EP4214240B1 (en) 2024-10-09
ES2995868T3 (en) 2025-02-11

Similar Documents

Publication Publication Date Title
US20230151112A1 (en) Immunoactivating antigen-binding molecule
US11660340B2 (en) Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
IL319478A (en) Anti-ccr8 antibodies
US11505605B2 (en) T cell-redirected antigen-binding molecule for cells having immunosuppression function
US11649293B2 (en) Method for enhancing humoral immune response
JP6971153B2 (ja) 多重特異的nkエンゲイジャータンパク質
KR20210143192A (ko) 변형된 Fc 단편, 이를 포함하는 항체 및 이의 응용
IL293385A (en) New anti–pd–1 antibodies
EP4493592A1 (en) Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
US12435159B2 (en) Anti-human GRP94 antibodies and uses
HK40100657A (en) Anti-ccr8 antibodies
HK40100657B (en) Anti-ccr8 antibodies
BR122025022218A2 (pt) Anticorpo anti-ccr8 e composição farmacêutica
BR122024013309B1 (pt) Anticorpos anti-ccr8 e composição compreendendo os mesmos
BR122024013309A2 (pt) Anticorpos anti-ccr8 e composição compreendendo os mesmos